Multiple-target Therapy for Posttransplant Focal Segmental Glomerulosclerosis.
Transplant Direct
; 10(6): e1651, 2024 Jun.
Article
in En
| MEDLINE
| ID: mdl-38817628
ABSTRACT
Background:
There is no consensus on the ideal strategy to treat posttransplant focal segmental glomerulosclerosis. The multiple-target therapy, which consisted of high-dose intravenous cyclosporine, prednisone, and plasmapheresis, showed favorable results.Methods:
This single-center, prospective study sought to evaluate the multiple-target therapy in an independent cohort of patients.Results:
Thirteen patients with posttransplant focal segmental glomerulosclerosis received multiple-target therapy. Complete remission was achieved in 2 patients (15.4%), and partial remission in another 2 patients (15.4%). Four patients (30.7%) did not show remission, and 5 patients (38%) lost the graft because of posttransplant focal segmental glomerulosclerosis during the 12-mo follow-up. Premature discontinuation of treatment occurred in 10 patients (77%), all associated with infectious adverse events. Cytomegalovirus was the most common complication, and preemptive therapy was used instead of prophylaxis.Conclusions:
In this cohort of patients, the efficacy of the multiple-target therapy was poor and limited by the high incidence of infectious adverse events.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Transplant Direct
Year:
2024
Document type:
Article
Affiliation country:
Brazil
Country of publication:
United States